The Role of Drug Exposure in Clinical Development: To What Extent Is Pharmacokinetic Assessment Needed in a Drug Development Programme?

Goyal, Navin

doi:10.1007/s40262-015-0287-x

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism of action of a compound, especially at an organism level, is not only dependent on the biological activity of the compound but also its exposure 1 , which can be defined by factors such as drug bioavailability, the volume of distribution , and clearance among other parameters. 2 One way to estimate drug exposure in vivo is the extrapolation from in vitro data (also known as IVIVE: in vitro to in vivo extrapolation).…”

Section: Introductionmentioning

confidence: 99%

PKSmart: An Open-Source Computational Model to Predictin vivoPharmacokinetics of Small Molecules

Seal,

Trapotsi,

Subramanian

et al. 2024

Preprint

View full text Add to dashboard Cite

Drug exposure is a key contributor to the safety and efficacy of drugs. It can be defined using human pharmacokinetics (PK) parameters that affect the blood concentration profile of a drug, such as steady-state volume of distribution (VDss), total body clearance (CL), half-life (t½), fraction unbound in plasma (fu) and mean residence time (MRT). In this work, we used molecular structural fingerprints, physicochemical properties, and predicted animal PK data as features to model the human PK parameters VDss, CL, t½, fu and MRT for 1,283 unique compounds. First, we predicted animal PK parameters [VDss, CL, fu] for rats, dogs, and monkeys for 372 unique compounds using molecular structural fingerprints and physicochemical properties. Second, we used Morgan fingerprints, Mordred descriptors and predicted animal PK parameters in a hyperparameter-optimised Random Forest algorithm to predict human PK parameters. When validated using repeated nested cross-validation, human VDss was best predicted with an R2of 0.55 and a Geometric Mean Fold Error (GMFE) of 2.09; CL with accuracies of R2=0.31 and GMFE=2.43, fu with R2=0.61 and GMFE=2.81, MRT with R2=0.28 and GMFE=2.49, and t½ with R2=0.31 and GMFE=2.46 for models combining Morgan fingerprints, Mordred descriptors and predicted animal PK parameters. We evaluated models with an external test set comprising 315 compounds for VDss (R2=0.33 and GMFE=2.58) and CL (R2=0.45 and GMFE=1.98). We compared our models with proprietary pharmacokinetic (PK) models from AstraZeneca and found that model predictions were similar with Pearson correlations ranging from 0.77-0.78 for human PK parameters of VDss and fu and 0.46-0.71 for animal (dog and rat) PK parameters of VDss, CL and fu. To the best of our knowledge, this is the first work that publicly releases PK models on par with industry-standard models. Early assessment and integration of predicted PK properties are crucial, such as in DMTA cycles, which is possible with models in this study based on the input of only chemical structures. We developed a webhosted application PKSmart (https://broad.io/PKSmart) which users can access using a web browser with all code also downloadable for local use.Abstract FigureFigure:For TOC Only

show abstract

Section: Introductionmentioning

confidence: 99%